首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   435558篇
  免费   29397篇
  国内免费   6884篇
耳鼻咽喉   5811篇
儿科学   8782篇
妇产科学   10602篇
基础医学   58819篇
口腔科学   12616篇
临床医学   37374篇
内科学   85749篇
皮肤病学   9066篇
神经病学   29860篇
特种医学   16126篇
外国民族医学   118篇
外科学   66735篇
综合类   20565篇
现状与发展   14篇
一般理论   67篇
预防医学   21470篇
眼科学   11014篇
药学   37141篇
  54篇
中国医学   6292篇
肿瘤学   33564篇
  2022年   3481篇
  2021年   5511篇
  2020年   4005篇
  2019年   4549篇
  2018年   6475篇
  2017年   5378篇
  2016年   5274篇
  2015年   6848篇
  2014年   9247篇
  2013年   10640篇
  2012年   14752篇
  2011年   15282篇
  2010年   9733篇
  2009年   8690篇
  2008年   12736篇
  2007年   13308篇
  2006年   13163篇
  2005年   12010篇
  2004年   10545篇
  2003年   10190篇
  2002年   9565篇
  2001年   29257篇
  2000年   29739篇
  1999年   24582篇
  1998年   5756篇
  1997年   4794篇
  1996年   4290篇
  1995年   3916篇
  1994年   3437篇
  1993年   3093篇
  1992年   16321篇
  1991年   15069篇
  1990年   14335篇
  1989年   14088篇
  1988年   12724篇
  1987年   12183篇
  1986年   11182篇
  1985年   10381篇
  1984年   6957篇
  1983年   5621篇
  1982年   2739篇
  1979年   5501篇
  1978年   3359篇
  1977年   2980篇
  1975年   2652篇
  1974年   3068篇
  1973年   2876篇
  1972年   2835篇
  1971年   2776篇
  1969年   2544篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
仝小林院士将新型冠状病毒肺炎定名为"寒湿疫",并以此理论为基础制定了初期、中期、重症期及恢复期的中医治疗方案,同时基于仝院士学术理论体系中的"脏腑风湿"理论,根据恢复期 "余毒未清,正虚邪恋"的病机特点,探讨其符合具备脏腑风湿行成3个基本要素:即外受寒湿裹挟戾气为必要外因;脏腑内虚为重要基础;邪疫伏留胶着,正邪交争为致病关键。故在辨证施治中可应用脏腑风湿理论以调理脾胃,化湿透邪,补益肺脾,顾护阳气,养阴生津。  相似文献   
5.
6.
7.
In the 6th Basic Plan for Long-Term Electricity Supply and Demand (6th BPE) for Korea, for the first time, the environmental costs of air pollution caused by oxides of sulfur (SOx), oxides of nitrogen (NOx), and particulate matters (PM) from power plants were estimated and included. However, several deficiencies in evaluating the environmental costs were found. In this study, (1) the validity of the environmental costs used in the 6th BPE was assessed, (2) a systematic approach was suggested and used to improve the environmental costs estimation, and (3) the sensitivity of the cost of generating electricity to the environmental costs by fuel type with the proposed approach was discussed. We found that the applied environmental costs used in the 6th BPE did not fully include the demographic characteristics of Korea. By applying more realistic parameter values, it was found that the newly estimated environmental cost was about 23 times higher than the cost estimated in the original 6th BPE for coal-fired power plants and about 1.5 times higher for liquefied natural gas (LNG)-fired power plants, suggesting that LNG-fired power plants are more economical if using more realistic environmental costs. Thus, it is critical to check the validity of parameter values when calculating environmental costs.  相似文献   
8.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号